SFM
CATX icon

Sphera Funds Management’s Perspective Therapeutics CATX Stock Holding History

Sphera Funds Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-349,973
Closed -$962K – 102
2025
Q4 		$962K Sell
349,973
-160,370
-31% -$458K 0.19% 86
2025
Q3 		$1.75M Buy
510,343
+200,000
+64% +$729K 0.37% 78
2025
Q2 		$1.07M Sell
310,343
-149,904
-33% -$396K 0.25% 86
2025
Q1 		$980K Hold
460,247
– – 0.23% 92
2024
Q4 		$1.47M Sell
460,247
-129,048
-22% -$1.05M 0.27% 88
2024
Q3 		$7.87M Sell
589,295
-197,614
-25% -$2.63M 1.25% 26
2024
Q2 		$7.85M Sell
786,909
-457,453
-37% -$6.61M 1.07% 30
2024
Q1 		$14.8M Buy
1,244,362
+1,241,795
+48,375% +$10.6M 2.08% 11
2023
Q4 		$10.3K Buy
+2,567
New +$7.23K ﹤0.01% 99

Other funds holding CATX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sphera Funds Management's CATX Position: Q1 2026 in Review

Sphera Funds Management sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 349,973 shares — an estimated $962K sold.

Sphera Funds Management first reported a position in CATX in Q4 2023 and held it in 9 quarters. The position peaked at $14.8M in Q1 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Sphera Funds Management reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sphera Funds Management sold 349,973 Perspective Therapeutics shares in Q1 2026, an estimated $962K.
  • Sphera Funds Management first reported a position in Perspective Therapeutics in Q4 2023 and held it in 9 quarters.
  • Sphera Funds Management's Perspective Therapeutics position peaked at $14.8M in Q1 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.